ClinConnect ClinConnect Logo
Search / Trial NCT05633056

An Adaptive Randomized Controlled Trial

Launched by COLUMBIA UNIVERSITY · Nov 21, 2022

Trial Information

Current as of July 01, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying how effective different types of support can be for adults with both multi-drug resistant tuberculosis (MDR-TB) and HIV. Participants will be given a treatment that includes Bedaquiline, a medication for MDR-TB, while also receiving antiretroviral therapy (ART) for HIV. The trial will compare four different approaches: standard medical care, psychosocial support (which helps with emotional and social aspects), mobile health technology that tracks medication use, and a combination of mobile health and psychosocial support. The goal is to find out which method helps patients the most during their treatment.

To participate in this trial, individuals must be adults aged 18 and older who have tested positive for both MDR-TB and HIV, and who are starting treatment soon. They should be able to give informed consent and will be excluded if they are pregnant or incarcerated. Participants can expect to receive support tailored to their needs, and their level of help may be adjusted based on what they require throughout the study. This trial is currently recruiting participants in KwaZulu-Natal, South Africa.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Culture or molecular test positive for MTB
  • 2. Molecular test positive for HIV or a documented HIV positive history
  • 3. Drug-susceptibility testing by molecular (i.e. GeneXpert MTB/RIF) or conventional testing consistent with at least rifampicin-resistant TB,
  • 4. Initiating treatment with a Bedaquiline -containing TB regimen within 4 weeks of enrollment and first-time being treated with BDQ
  • 5. On treatment with Antiretroviral Therapy (ART) regimen, including dolutegravir-containing combination Antiretroviral Therapy regimen (i.e. Tenofovir-Lamivudine-Dolutergravir), or starting within 4 weeks of enrollment,
  • 6. Capacity for informed consent in either isiZulu or English
  • Exclusion Criteria:
  • 1. Pregnancy
  • 2. Prisoners
  • 3. Discretion of IOR or clinician

About Columbia University

Columbia University, a prestigious Ivy League institution located in New York City, is a leading sponsor of clinical trials dedicated to advancing medical research and improving patient care. With a robust network of research facilities and a commitment to innovation, Columbia University collaborates with a diverse range of healthcare professionals and researchers to explore groundbreaking therapies and treatment methodologies. The university's clinical trials encompass various fields, including oncology, neurology, and public health, aiming to translate scientific discoveries into effective clinical applications. Columbia University is dedicated to maintaining the highest ethical standards and regulatory compliance, ensuring the safety and well-being of trial participants while contributing to the global body of medical knowledge.

Locations

Durban, Kwazulu Natal, South Africa

Patients applied

0 patients applied

Trial Officials

Max O'Donnell, Prof

Principal Investigator

University of Columbia

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials